# Multicenter Study to Evaluate CRx-102 vs. Each of Its Components to Treat Active Rheumatoid Arthritis

> **NCT00551707** · PHASE2 · COMPLETED · sponsor: **Zalicus** · enrollment: 51 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** CRx-102 (2.7/180)
- **DRUG:** prednisolone
- **DRUG:** dipyridamole
- **DRUG:** placebo
- **DRUG:** CRx-102 (2.7/360)

## Key facts

- **NCT ID:** NCT00551707
- **Lead sponsor:** Zalicus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-11
- **Final completion:** 2009-01
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2014-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00551707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00551707, "Multicenter Study to Evaluate CRx-102 vs. Each of Its Components to Treat Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00551707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*